Jose Luis Sanchez-Quesada

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7288089/publications.pdf

Version: 2024-02-01

66 papers

1,745 citations

23 h-index 39 g-index

67 all docs

67
docs citations

67 times ranked

1839 citing authors

#	Article	IF	CITATIONS
1	Heparin binding triggers human VLDL remodeling by circulating lipoprotein lipase: Relevance to VLDL functionality in health and disease. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2022, 1867, 159064.	1.2	5
2	Assessment of Ex Vivo Potential of Murine HDL in. Methods in Molecular Biology, 2022, 2419, 283-292.	0.4	O
3	Monitoring Atheroprotective Macrophage Cholesterol. Methods in Molecular Biology, 2022, 2419, 569-581.	0.4	1
4	Plasma sICAM-1 as a Biomarker of Carotid Plaque Inflammation in Patients with a Recent Ischemic Stroke. Translational Stroke Research, 2022, 13, 745-756.	2.3	6
5	Atherogenicity of low-density lipoproteins after switching from a protease inhibitor to dolutegravir: a substudy of the NEATO22 study. Journal of Antimicrobial Chemotherapy, 2022, , .	1.3	1
6	Exploratory analysis of large-scale lipidome in large cohorts: are we any closer of finding lipid-based markers suitable for CVD risk stratification and management?. Analytica Chimica Acta, 2021, 1142, 189-200.	2.6	7
7	Comparison of Plasma Lipoprotein Composition and Function in Cerebral Amyloid Angiopathy and Alzheimer's Disease. Biomedicines, 2021, 9, 72.	1.4	7
8	Cardiovascular Disease in Type 1 Diabetes Mellitus: Epidemiology and Management of Cardiovascular Risk. Journal of Clinical Medicine, 2021, 10, 1798.	1.0	21
9	Changes in the Composition and Function of Lipoproteins after Bariatric Surgery in Patients with Severe Obesity. Journal of Clinical Medicine, 2021, 10, 1716.	1.0	8
10	Autoimmune Rheumatic Diseases: An Update on the Role of Atherogenic Electronegative LDL and Potential Therapeutic Strategies. Journal of Clinical Medicine, 2021, 10, 1992.	1.0	5
11	Do All Integrase Strand Transfer Inhibitors Have the Same Lipid Profile? Review of Randomised Controlled Trials in NaÃ-ve and Switch Scenarios in HIV-Infected Patients. Journal of Clinical Medicine, 2021, 10, 3456.	1.0	13
12	Mini-extracorporeal circulation surgery produces less inflammation than off-pump coronary surgery. European Journal of Cardio-thoracic Surgery, 2020, 57, 496-503.	0.6	5
13	Low-density lipoprotein aggregation is inhibited by apolipoprotein J-derived mimetic peptide D-[113–122]apoJ. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158541.	1.2	7
14	Lipids, biomarkers, and subclinical atherosclerosis in treatment-naive HIV patients starting or not starting antiretroviral therapy: Comparison with a healthy control group in a 2-year prospective study. PLoS ONE, 2020, 15, e0237739.	1.1	10
15	Subcutaneous Administration of Apolipoprotein J-Derived Mimetic Peptide d-[113–122]apoJ Improves LDL and HDL Function and Prevents Atherosclerosis in LDLR-KO Mice. Biomolecules, 2020, 10, 829.	1.8	18
16	Electronegative LDL Promotes Inflammation and Triglyceride Accumulation in Macrophages. Cells, 2020, 9, 583.	1.8	32
17	Familial Combined Hyperlipidemia (FCH) Patients with High Triglyceride Levels Present with Worse Lipoprotein Function Than FCH Patients with Isolated Hypercholesterolemia. Biomedicines, 2020, 8, 6.	1.4	5
18	Effects of Bariatric Surgery on HDL Cholesterol. Obesity Surgery, 2020, 30, 1793-1798.	1.1	11

#	Article	IF	Citations
19	Binding to heparin triggers deleterious structural and biochemical changes in human low-density lipoprotein, which are amplified in hyperglycemia. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2020, 1865, 158712.	1.2	4
20	The Role of Distinctive Sphingolipids in the Inflammatory and Apoptotic Effects of Electronegative LDL on Monocytes. Biomolecules, 2019, 9, 300.	1.8	14
21	Plasma microRNA Profiling Reveals Novel Biomarkers of Epicardial Adipose Tissue: A Multidetector Computed Tomography Study. Journal of Clinical Medicine, 2019, 8, 780.	1.0	13
22	Molecular basis for the protective effects of low-density lipoprotein receptor-related protein 1 (LRP1)-derived peptides against LDL aggregation. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 1302-1316.	1.4	10
23	Peripheral administration of human recombinant ApoJ/clusterin modulates brain beta-amyloid levels in APP23 mice. Alzheimer's Research and Therapy, 2019, 11, 42.	3.0	29
24	Effects of triacylglycerol on the structural remodeling of human plasma very low- and low-density lipoproteins. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2019, 1864, 1061-1071.	1.2	8
25	Sulfate-based lipids: Analysis of healthy human fluids and cell extracts. Chemistry and Physics of Lipids, 2019, 221, 53-64.	1.5	17
26	Human ApoA-I Overexpression Enhances Macrophage-Specific Reverse Cholesterol Transport but Fails to Prevent Inherited Diabesity in Mice. International Journal of Molecular Sciences, 2019, 20, 655.	1.8	6
27	Electronegative LDL: An Active Player in Atherogenesis or a By-Product of Atherosclerosis?. Current Medicinal Chemistry, 2019, 26, 1665-1679.	1.2	14
28	Soluble LRP1 is an independent biomarker of epicardial fat volume in patients with type 1 diabetes mellitus. Scientific Reports, 2018, 8, 1054.	1.6	11
29	Associations between epicardial adipose tissue, subclinical atherosclerosis and high-density lipoprotein composition in type 1 diabetes. Cardiovascular Diabetology, 2018, 17, 156.	2.7	26
30	Electronegative LDL induces MMP-9 and TIMP-1 release in monocytes through CD14 activation: Inhibitory effect of glycosaminoglycan sulodexide. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2018, 1864, 3559-3567.	1.8	19
31	Modified low-density lipoproteins as biomarkers in diabetes and metabolic syndrome. Frontiers in Bioscience - Landmark, 2018, 23, 1220-1240.	3.0	17
32	Differential effects of apoE and apoJ mimetic peptides on the action of an anti-A $\hat{1}^2$ scFv in 3xTg-AD mice. Biochemical Pharmacology, 2018, 155, 380-392.	2.0	17
33	Increased inflammatory effect of electronegative LDL and decreased protection by HDL in type 2 diabetic patients. Atherosclerosis, 2017, 265, 292-298.	0.4	14
34	Characterization of ApoJ-reconstituted high-density lipoprotein (rHDL) nanodisc for the potential treatment of cerebral \hat{l}^2 -amyloidosis. Scientific Reports, 2017, 7, 14637.	1.6	31
35	Triglyceride increase in the core of high-density lipoproteins augments apolipoprotein dissociation from the surface: Potential implications for treatment of apolipoprotein deposition diseases. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2017, 1863, 200-210.	1.8	13
36	Inflammatory intracellular pathways activated by electronegative LDL in monocytes. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 963-969.	1.2	18

#	Article	IF	Citations
37	Thermal stability of human plasma electronegative low-density lipoprotein: A paradoxical behavior of low-density lipoprotein aggregation. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2016, 1861, 1015-1024.	1.2	6
38	The role of LDL-bound apoJ in the development of atherosclerosis. Clinical Lipidology, 2015, 10, 321-328.	0.4	5
39	Hypoxia worsens the impact of intracellular triglyceride accumulation promoted by electronegative low-density lipoprotein in cardiomyocytes by impairing perilipin 5 upregulation. International Journal of Biochemistry and Cell Biology, 2015, 65, 257-267.	1.2	12
40	Increased concentration of clusterin/apolipoprotein J (apoJ) in hyperlipemic serum is paradoxically associated with decreased apoJ content in lipoproteins. Atherosclerosis, 2015, 241, 463-470.	0.4	15
41	Clusterin/apolipoprotein J binds to aggregated LDL in human plasma and plays a protective role against LDL aggregation. FASEB Journal, 2015, 29, 1688-1700.	0.2	25
42	Ceramide-enriched LDL induces cytokine release through TLR4 and CD14 in monocytes. Similarities with electronegative LDL. ClÃnica E Investigación En Arteriosclerosis, 2014, 26, 131-137.	0.4	17
43	Bariatric surgery in morbidly obese patients improves the atherogenic qualitative properties of the plasma lipoproteins. Atherosclerosis, 2014, 234, 200-205.	0.4	29
44	Modified lipoproteins as biomarkers of cardiovascular risk in diabetes mellitus. EndocrinologÃa Y Nutrición (English Edition), 2013, 60, 518-528.	0.5	7
45	Impact of the LDL subfraction phenotype on Lp-PLA2 distribution, LDL modification and HDL composition in type 2 diabetes. Cardiovascular Diabetology, 2013, 12, 112.	2.7	47
46	CD14 and TLR4 mediate cytokine release promoted by electronegative LDL in monocytes. Atherosclerosis, 2013, 229, 356-362.	0.4	56
47	LipoproteÃnas modificadas como marcadores de riesgo cardiovascular en la diabetes mellitus. Endocrinologia Y Nutricion: Organo De La Sociedad Espanola De Endocrinologia Y Nutricion, 2013, 60, 518-528.	0.8	14
48	The Induction of Cytokine Release in Monocytes by Electronegative Low-Density Lipoprotein (LDL) Is Related to Its Higher Ceramide Content than Native LDL. International Journal of Molecular Sciences, 2013, 14, 2601-2616.	1.8	23
49	Electronegative LDL: A Circulating Modified LDL with a Role in Inflammation. Mediators of Inflammation, 2013, 2013, 1-13.	1.4	41
50	LDL subclasses and lipoprotein-phospholipase A2 activity in suppressed HIV-infected patients switching to raltegravir: Spiral substudy. Atherosclerosis, 2012, 225, 200-207.	0.4	30
51	HDL and electronegative LDL exchange anti- and pro-inflammatory properties. Journal of Lipid Research, 2010, 51, 2947-2956.	2.0	24
52	Aggregated Electronegative Low Density Lipoprotein in Human Plasma Shows a High Tendency toward Phospholipolysis and Particle Fusion. Journal of Biological Chemistry, 2010, 285, 32425-32435.	1.6	46
53	High binding affinity of electronegative LDL to human aortic proteoglycans depends on its aggregation level. Journal of Lipid Research, 2009, 50, 446-455.	2.0	31
54	Standardization of a method to evaluate the antioxidant capacity of high-density lipoproteins. International Journal of Biomedical Science, 2009, 5, 402-10.	0.5	8

#	Article	IF	CITATIONS
55	Pro-inflammatory action of LDL(â^') on mononuclear cells is counteracted by increased IL10 production. Biochimica Et Biophysica Acta - Molecular and Cell Biology of Lipids, 2007, 1771, 613-622.	1.2	34
56	Human Apolipoprotein A-II Enrichment Displaces Paraoxonase From HDL and Impairs Its Antioxidant Properties. Circulation Research, 2004, 95, 789-797.	2.0	118
57	Effect of simvastatin in familial hypercholesterolemia on the affinity of electronegative low-density lipoprotein subfractions to the low-density lipoprotein receptor. American Journal of Cardiology, 2004, 93, 414-420.	0.7	43
58	Impaired Binding Affinity of Electronegative Low-Density Lipoprotein (LDL) to the LDL Receptor Is Related to Nonesterified Fatty Acids and Lysophosphatidylcholine Contentâ€. Biochemistry, 2004, 43, 15863-15872.	1.2	49
59	Electronegative low-density lipoprotein. Current Opinion in Lipidology, 2004, 15, 329-335.	1.2	109
60	Electronegative LDL of FH subjects: chemical characterization and induction of chemokine release from human endothelial cells. Atherosclerosis, 2003, 166, 261-270.	0.4	96
61	Platelet-Activating Factor Acetylhydrolase Is Mainly Associated With Electronegative Low-Density Lipoprotein Subfraction. Circulation, 2003, 108, 92-96.	1.6	101
62	Changes in low-density lipoprotein electronegativity and oxidizability after aerobic exercise are related to the increase in associated non-esterified fatty acids. Atherosclerosis, 2002, 160, 223-232.	0.4	77
63	Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects. Journal of Lipid Research, 2002, 43, 699-705.	2.0	81
64	Density distribution of electronegative LDL in normolipemic and hyperlipemic subjects. Journal of Lipid Research, 2002, 43, 699-705.	2.0	66
65	Prevalence and Phenotypic Distribution of Dyslipidemia in Type 1 Diabetes Mellitus. Archives of Internal Medicine, 2000, 160, 2756.	4.3	63
66	Susceptibility of plasma low- and high-density lipoproteins to oxidation in patients with severe hyperhomocysteinemia. Journal of Molecular Medicine, 1996, 74, 771-776.	1.7	29